Cervical Dysplasia and HPV

Similar documents
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

Colposcopy. Attila L Major, MD, PhD

Understanding Your Pap Test Results

Making Sense of Cervical Cancer Screening

Human Papillomavirus

CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN)

Cervical Conization. 1

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

Management of Abnormal Cervical Cytology and Histology

Becoming a colposcopist: Colposcope case studies

Eradicating Mortality from Cervical Cancer

Human Papillomavirus (HPV) and Cervical Cancer Prevention

Cervical Cancer 4/27/2016

Cervical Cancer Screening. David Quinlan December 2013

Your Colposcopy Visit

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

No Disclosures. Updated Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results. Objectives 5/9/2016

Cervical Cancer : Pap smear

The society for lower genital tract disorders since 1964.

chapter 4. The effect of oncogenic HPV on transformation zone epithelium

Chapter 10: Pap Test Results

To further assess abnormalities detected on cervical cytological sample. To guide colposcopically directed biopsy

Clinical Practice Guidelines June 2013

What is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Harris Health System

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests

International Federation of Gynecology and Obstetrics

Cervical Cancer Screening Update. Melissa Hartman, DO Women s Health

Introduction to Colposcopy

Lauren O Sullivan, D.O. February 19, 2015

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

Treatment of Cervical Intraepithelial Neoplasia. Case. How would you manage this woman?

Cervical Screening for Dysplasia and Cancer in Patients with HIV

GLANDULAR LESIONS PITFALLS IN MANAGEMENT. Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016

Management that provides continuity of care for women

WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

Estimated New Cancers Cases 2003

cle Modern management of abnormal cervical smear Tint Tint Wai and Dilip Patil BJMP 2008:1(2) 18-22

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

I have no financial interests to disclose.

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

Cervical Cancer Screening Guidelines Update

HPV, Cervical Dysplasia and Cancer

What Causes Cervical Cancer? Symptoms of Cervical Cancer

I have no financial interests in any product I will discuss today.

PREINVASIVE DISEASE OF THE LOWER GENITAL TRACT DR AI LING TAN GYNAECOLOGICAL ONCOLOGIST ASCOT CLINIC,ADHB

Running head: EVIDENCE-BASED MEDICINE TWO-STEP DISCREPANCY

Histopathology: Cervical HPV and neoplasia

Done by khozama jehad. Neoplasia of the cervix

Focus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection

Managament of Abnormal Cervical Cytology and Histology

Cervical Cancer Screening

Human Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?

Human Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita

Woo Dae Kang, Ho Sun Choi, Seok Mo Kim

HPV infections and potential outcomes

LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

Jean Anderson, MD Catherine Sewell, MD, MPH

HKCOG GUIDELINES NUMBER 3 (revised November 2002) published by The Hong Kong College of Obstetricians and Gynaecologists

SESSION J4. What's Next? Managing Abnormal PAPs in 2014

SOGC / SCC Clinical Practice Guideline

SQUAMOUS CELLS: Atypical squamous cells (ASC) - of undetermined significance (ASC-US) - cannot exclude HSIL (ASC-H)

Comparative Study of Pap Smear Quality by using Ayre s Spatula versus Ayre s Spatula and Cytobrush Combination

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT

Objectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies

Cervical Precancer: Evaluation and Management

What is a Pap smear?

Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.

MINISTRY OF HEALTH. CANCER of the CERVIX and its PREVENTION A FACT BOOK FOR HEALTH WORKERS

Colposcopic Principles. Simon Leeson Consultant Obstetrician/ Gynaecologist Betsi Cadwaladr University Health Board UK

COLPOSCOPY MADE EASY AND SIMPLE

COMPARATIVE STUDY OF LIQUID BASED CYTOLOGY AND PAP SMEAR IN CANCER CERVIX SCREENING

Understand Your Results

Streamlining Protocols-From Strategy to Implementation. Doreen Ramogola-Masire Botswana UPenn Partnership June 2014

New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma

PREVENTION OF CERVICAL CANCER

CERVIX. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb.

Updated ASCCP Consensus Guidelines For Managing Diagnosed Cervical Cancer Precursors Michael A. Gold, M.D.

Samuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida

Cervical Skills. Dr Margaret Laing Queen Elizabeth University Hospital

Cervical Cancer Screening

Over-diagnoses in Cytopathology: Is histology the gold standard?

5. Colposcopist performing exam: (Draw SCJ, acetowhite, punctation, mosaics, atypical vessels, and other lesions)

Update of the role of Human Papillomavirus in Head and Neck Cancer

Cytyc Corporation - Case Presentation Archive - July 2002

Cervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix

I have no financial interests in any product I will discuss today.

CPC on Cervical Pathology

The Pap Smear Test. The Lebanese Society of Obstetrics and Gynecology. Women s health promotion series

10/31/2017. Disclosures. I. Background: History 1,4. Cervical Cancer Screening and HPV

HPV-related papillomatous-condylomatous lesions in female anogenital area

Transcription:

Cervical Dysplasia and HPV J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse HPV Double stranded DNA virus The HPV infect epithelial cells of the skin and mucous membranes Highest risk types to cause cancer: 16,18, 31, 33, 35,39, 45, 51, 52, 56, 58, 59 HPV and Cancer 15% of cancers are caused by viruses HPV accounts for 600,000 cases yearly Anal, Cervix, Oropharyngeal, Vulvovaginal, and penile HPV 16 and 18 are the most oncogenic types 1

HPV and Cervical Cancer Squamous cell carcinoma (69%) HPV 16 (59%), HPV 18 (13%), HPV 58 (5%), HPV 45 (4%) Adenocarcinoma (25%) HPV 16 (36%), HPV 18 (37%), HPV 45 (5%), HPV 31 (2%), HPV 33 (2%) HPV Natural History Even with prevalence rates noted, most HPV infection is cleared by immune system Studies show 1 year clearance rates of 40 70% with 2 5 year clearance rates of 70 100% Younger women clear quicker than older women Low risk HPV clears quicker than high risk HPV 16, 31, 54, and 53 are associated with longest persistent infection 2

Transmission Sexual exposure is most common through skin and mucosal surfaces Genital genital, oral genital, anal genital, or oral anal contact Condoms may not be fully protective due to HPV found on areas of the vulva and scrotum HPV causing cervical dysplasia Most affected area is transformation zone (squamo columnar junction) CIN has nuclear atypia which happens when the HPV infects the cell and replicates Basaloid cells are a single layer in contact with the basement membrane. These cells can show crowding, abnormal mitosis, loss of polarity and the extent of abnormal basaloid cells will determine grade of CIN CIN 1 = undifferentiated basaloid cells involve lower 1/3 of the epithelium CIN 2 = lower 2/3 of epithelium CIN 3 = >2/3 of the epithelium Squamo columnar junction Original Junction in fetal life between stratified squamous epithelium of the vagina and columnar epithelium of the endocervical canal New Increasing estrogen and acidity of the vagina causes damage to the columnar epithelium which becomes replaced by immature squamous metaplasia that matures to stratified squamous metaplastic epithelium The original junctional zone is replace by a zone of squamous metaplasia and the upper margin of this zone is an area of morphologically squamous cells and colposcopy columnar cells This is the new squamo columnar junction 3

Transformation Zone Area between the original squamo columnar junction and the new squamo columnar junction Cervical neoplasia arises in this area HPV and cervical cancer HOW??? 4 steps in the development of cancer Infection of the metaplastic epithelium of the transformation zone with carcinogenic HPV Viral persistence Progression of infected epithelium to precancer (CIN3) Invasion 4

Screening for cervical cancer PAP (Papanicolaou) smear Cervical and vaginal cytology Identify cells from the transformation zone and ectocervix / endocervix junction Easier to detect squamous lesions than adeno lesions Due to adenocarcinoma forming skip lesions and being in endocervix Since using PAP the incidence of cervical cancer decreased from 36.3 to 7.2 per 100,000 Despite PAP smears the risk of cervical cancer in those properly screened are 20 30% Due to poor cellularity in collection or transfer Inflammation of the cervix, scant cellularity, blood obscuring Rates of unsatisfactory PAP is 1 8% HPV testing overcomes these human error problems PAP Smear Conventional screening Cells sampled from cervix and vagina with a brush or spatula and directly placed on a slide and fixed HPV collected separate Liquid based screening Cells collected the same but placed in liquid transport media and spun / filtered in the lab HPV can be run on this specimen 5

Screening Guidelines ACS, ASCCP and ASCP say to screen with cytology every 3 years starting at 21 y/o No HPV testing because HPV infection usually transient and increase risk of procedures / colposcopy At age 30 y/o co testing with cytology and HPV testing Screening every 5 years if both are negative HPV more persistent in this age group and clinical significance is greater If no HPV test then cytology every 3 years Screening Guidelines HIV patients Yearly screening, ability of HPV clearance is low Immunocompromised (systemic disease / transplants) Yearly PAP and HPV from 21 y/o and up Prior hysterectomy for CIN 2/3 Screen for 20 years HPV causes changes in guidelines Patients with negative PAP but HPV 16 or 18 + should have a colposcopy LSIL or ASCUS PAP with HPV negative can be monitored HPV is now used to triage how to treat abnormal cytology 6

Why do we screen? To detect precancerous lesions and early stage disease Decrease the mortality and incidence of cervical cancer Studies show higher cure rates and decreased risk of invasive cervical cancer PAP smears ASCUS atypical squamous cells of undetermined significance 5 27% will have a CIN 2/3 lesions 0.2% have cervical carcinoma ASC H atypical squamous cells cannot exclude a high grade lesion 40% have a CIN 2/3 lesion LSIL Low grade squamous intraepithelial lesion 25% have a CIN 2/3 lesion HSIL High grade squamous intraepithelial lesion Up to 66% have CIN 2/3 lesions AGS Atypical glandular cells 9 38% have carcinoma in site or invasive cancer HPV Vaccine 2 are FDA approved Quadrivalent type (Gardasil) Contains VLPs to HPV 6, 11, 16, 18 Injection given 0, 2 and 6 months Age 9 26 Bivalent (Cervarix) VLPs to 16 and 18 Injection given 0, 1, and 6 months Age 15 25 7

HPV Vaccine The L1 capsid protein was the target for a vaccine The vaccine has recombinant L1 protein that forms virus like particles that are combined with different adjuvants the adjuvants stimulate the immune system and increase response to vaccine Response produced is mostly humoral response with antibodies but it also can have a cell mediated response How well does vaccine work? Study of 17,000 HPV naïve women aged 16 26 showed the quadrivalent vaccine prevented 99% of HPV 16 or 18 preinvasive or invasive lesions Similar studies of the bivalent showed 100% of HPV 16 and 18 mediated CIN 3 lesions were prevented There was less effect on those already affected with HPV which lends idea that this is more of a prophylactic vaccine CIN history Cervical Intraepithelial neoplasia CIN 1 Few convert to higher grade lesions (4 10%) Most persist or regress away CIN 2/3 More high risk At least 30% become invasive cancer without treatment 8

Unsatisfactory Cytology Cytology normal, EC cells absent / insufficient PAP negative, HPV + 9

ASC US 21 24 y/o with ASC US or LSIL LSIL PAP Management 10

Pregnant woman with LSIL Management of ASC H Management of 21 24 y/o with ASC H and HSIL 11

Management of HSIL AGC Workup 12

Colposcopy Initial exam of cervix should look for Hyperkeratosis which is a white, thickened epithelial area of the cervix Atypical vessels which can be seen by green filtered light 3 5% acetic acid then placed Acetowhite epithelium Atypical vessels termed mosaicism and punctation Lugols iodine (schillers test) Normal tissue has glycogen and stains mahogany brown Neoplastic tissue do not and stain mustard yellow 13

ECC / Cervical Biopsy Performed to exclude occult cancer in the canal Can omit when entire SCJ can be visualized Biopsy any and all abnormal cervical lesions Colposcopy Grading Normal Low grade disease (CIN 1) High grade disease (CIN 2,3) Invasive Cancer Management of AGC 14

Management of CIN 1 21 24 y/o with no CIN 1 but abnormal PAP 15

Management of CIN 2 or 3 Management of 21 24 y/o with CIN 2,3 AIS 16

Treatment of dysplasia Ablative Cryosurgery Electrocoagulation diathermy CO2 laser Excisional procedure LEEP Excisional cone (CKC) Hysterectomy Cryosurgery Cyronecrosis of the lesion through compressed nitrous oxide Crystallization of intracellular water results in cell death Must cover a 5 mm depth and a 7 mm lateral spread Probe must cove entire lesion and transformation zone Usually only for smaller lesions and ectocervical lesions Freeze thaw freeze technique where you freeze a second time in order to ensure proper treatment of the cervical lesion Watery, malodorous, blood tinged discharge for 2 3 weeks 17

Loop Electrosurgical Excision Procedure Excisional procedure Locate lesion and select correct loop You want to have 2 mm lateral on both sides of the lesion and a depth of 5 7 mm ECC or cowboy hat biopsy of cervical canal Cauterize the cervical area or place monsels CO2 Laser Using CO2 laser to ablate a lesion and the transformation zone Ablate to a depth of 7 10 mm 18

Cold Knife Conization Procedure Locate lesion Stitches at 3 and 9 o'clock for hemostasis and traction 11 blade scalpel to excise lesion ECC done Cauterize cervix / stitches / monsel Higher cure rates for high grade CIN Especially important when you need to have clean margins (i.e AIS) 19

ASCCP Guidelines should be use to help you evaluate and treat patients Remember guidelines are the minimum you need to do for your patient When in doubt do a biopsy or colposcopy if the lesion looks more high grade to you 20